Stock Events

Stock Events

Abivax 

$118.24
89
+$0+0% Today

Statistics

Day High
120.85
Day Low
120.85
52W High
133.4
52W Low
5.81
Volume
100
Avg. Volume
454
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MayExpected
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-2.1
-1.62
-1.14
-0.66
Expected EPS
-0.8077192163805138
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-367.82MNet Income

Analyst Ratings

$145.56Average Price Target
The highest estimate is 176.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
11%
Sell
11%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AAVXF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes with Abivax in the development of antiviral drugs, including treatments for HIV, which is a focus area for Abivax.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is involved in creating antiviral treatments and therapies for infectious diseases, competing directly with Abivax's efforts in HIV and other viral infections.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, including therapies for HIV/AIDS, positioning it as a competitor to Abivax.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline plc focuses on developing and marketing vaccines and medications for HIV, directly competing with Abivax's research and development in HIV treatments.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, works on developing treatments for infectious diseases, including HIV, making it a competitor to Abivax.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie Inc. competes in the area of antiviral research, with a focus on therapies for HIV, hepatitis, and other viral infections, areas that Abivax is also targeting.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including antiviral drugs, competing with Abivax in the infectious disease space.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is engaged in the discovery and development of prescription medicines for various diseases, including HIV/AIDS, making it a direct competitor to Abivax.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. is known for its work in biotechnology and the development of medicines for infectious diseases, competing with Abivax in the biopharmaceutical field.
Novartis
NVS
Mkt Cap297.32B
Novartis AG is a global healthcare company that researches and develops treatments for a wide range of diseases, including viral infections, competing with Abivax in the pharmaceutical and healthcare market.

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Show more...
CEO
Mr. Didier Blondel
Employees
69
Country
US
ISIN
FR0012333284

Listings

F
DE
2X10.F
XETRA
DE
2X1.XETRA
OTC Link
US
AAVXF
BOATS
BOATS
ABVX.BOATS

0 Comments

Share your thoughts

FAQ

What is Abivax stock price today?▼
The current price of AAVXF is $118.24 USD — it has increased by +0% in the past 24 hours. Watch Abivax stock price performance more closely on the chart.
What is Abivax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Abivax stocks are traded under the ticker AAVXF.
When is the next Abivax earnings date?▼
Abivax is going to release the next earnings report on May 25, 2026.
What were Abivax earnings last quarter?▼
AAVXF earnings for the last quarter are -1.22 USD per share, whereas the estimation was -1.36 USD resulting in a +10.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Abivax revenue for the last year?▼
Abivax revenue for the last year amounts to 0 USD.
What is Abivax net income for the last year?▼
AAVXF net income for the last year is -367.82M USD.
How many employees does Abivax have?▼
As of April 06, 2026, the company has 69 employees.
In which sector is Abivax located?▼
Abivax operates in the Health Care sector.
When did Abivax complete a stock split?▼
Abivax has not had any recent stock splits.
Where is Abivax headquartered?▼
Abivax is headquartered in Paris, US.